Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   39572   clinical trials with a EudraCT protocol, of which   6487   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2020-002584-63
    Sponsor's Protocol Code Number:VAC31518COV2001
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Temporarily Halted
    Date on which this record was first entered in the EudraCT database:2020-10-16
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2020-002584-63
    A.3Full title of the trial
    A Randomized, Double-blind, Placebo-controlled Phase 2a Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults Aged 18 to 55 Years Inclusive and Adults Aged 65 Years and Older
    “Estudio fase 2a, aleatorizado, doble ciego, controlado con placebo, para evaluar un rango de niveles de dosis e intervalos de vacunación de Ad26.COV2.S en adultos sanos de 18 a 55 años inclusive y adultos de 65 años en adelante.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Study to Evaluate Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults Aged 18 to 55 Years Inclusive and Adults Aged 65 Years and Older
    Estudio para evaluar un rango de dosis e intervalos de vacunación de Ad26.COV2.S en adultos sanos de 18 a 55 años inclusive y adultos de 65 años en adelante.
    A.4.1Sponsor's protocol code numberVAC31518COV2001
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorJanssen Vaccines & Prevention B.V.
    B.1.3.4CountryNetherlands
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportJanssen Vaccines & Prevention B.V.
    B.4.2CountryNetherlands
    B.4.1Name of organisation providing supportBiomedical Advanced Research and Development Authority (BARDA)
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationJanssen-Cilag S.A.
    B.5.2Functional name of contact pointGlobal Clinical Operations
    B.5.3 Address:
    B.5.3.1Street AddressPaseo de las Doce Estrellas 5-7
    B.5.3.2Town/ cityMadrid
    B.5.3.3Post code28042
    B.5.3.4CountrySpain
    B.5.4Telephone number34607016691
    B.5.5Fax number34917228628
    B.5.6E-mailcaparici@its.jnj.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameAd26.COV2.S (also known as Ad26COVS1)
    D.3.2Product code VAC31518
    D.3.4Pharmaceutical form Suspension for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntramuscular use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNot available
    D.3.9.2Current sponsor codeVAC31518
    D.3.9.3Other descriptive nameAd26.COV2.S (also known as Ad26COVS1)
    D.3.9.4EV Substance CodeSUB208328
    D.3.10 Strength
    D.3.10.1Concentration unit billion organisms/ml billion organisms/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) Yes
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms Yes
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameAd26.COV2.S (also known as Ad26COVS1)
    D.3.2Product code VAC31518
    D.3.4Pharmaceutical form Suspension for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntramuscular use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNot available
    D.3.9.2Current sponsor codeVAC31518
    D.3.9.3Other descriptive nameAd26.COV2.S (also known as Ad26COVS1)
    D.3.9.4EV Substance CodeSUB208328
    D.3.10 Strength
    D.3.10.1Concentration unit billion organisms/ml billion organisms/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number200
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) Yes
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms Yes
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for injection
    D.8.4Route of administration of the placeboIntramuscular use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Healthy Volunteers (Prevention of COVID-19)
    Voluntarios sanos (prevención de la COVID-19)
    E.1.1.1Medical condition in easily understood language
    Healthy Volunteers (Prevention of COVID-19)
    Voluntarios sanos (prevención de la COVID-19)
    E.1.1.2Therapeutic area Diseases [C] - Virus Diseases [C02]
    MedDRA Classification
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    1. To assess the humoral immune response to 3 dose levels (5x10^10 virus particle (vp), 2.5x10^10 vp, 1.25x10^10 vp) of Ad26.COV2.S, administered intramuscularly (IM) as a 2-dose schedule at a 56-day interval, 28 days after Vaccination 2.
    2. To assess the humoral immune response to 2 dose levels (1 x10^11 vp and 5x10^10 vp) of Ad26.COV2.S, administered IM as a single vaccination, 28 days after Vaccination 1.
    3. To assess the humoral immune response to Ad26.COV2.S at the 5x10^10 vp dose level, administered IM as a 2-dose schedule at a 28-day and at an 84-day interval, 28 days after Vaccination 2.
    4. To assess the safety and reactogenicity of Ad26.COV2.S, administered IM at several dose levels, as a 2-dose or a single-dose schedule.
    1.Evaluar la respuesta inmunitaria humoral en 3 niveles de dosis (5x1010 partículas víricas (pv), 2,5x1010 pv, 1,25x1010 pv) de Ad26.COV2.S, administrados de forma intramuscular (IM) como una pauta de 2 dosis en un intervalo de 56 días, 28 días después de la vacunación 2.
    2.Evaluar la respuesta inmunitaria humoral en 2 niveles de dosis (1x1011 pv y 5x1010 pv) de Ad26.COV2.S, administrados IM como una vacuna única, 28 días después de la vacunación 1.
    3.Evaluar la respuesta inmunitaria humoral a Ad26.COV2.S en el nivel de dosis de 5x1010 pv, administrado IM como una pauta de 2 dosis en un intervalo de 28 días y de 84 días, 28 días después de la vacunación 2.
    4.Evaluar la seguridad y la reactogenicidad de Ad26.COV2.S, administrada IM en múltiples niveles de dosis, como una pauta de 2 dosis o de dosis única.
    E.2.2Secondary objectives of the trial
    1. To assess the anamnestic response to antigen presentation of Ad26.COV2.S at the 1.25x10^10 vp dose level, administered 4 months after Vaccination 2 (2-dose schedule) or 6 months after a Vaccination 1 (single-dose schedule), 7 days after antigen presentation.
    2. To assess the safety and reactogenicity of antigen presentation of Ad26.COV2.S at the 1.25x10^10 vp dose level, administered 4 months after Vaccination 2 (2-dose schedule) or 6 months after a Vaccination 1 (single-dose schedule).
    3. To assess the humoral immune response to Ad26.COV2.S across all groups, at all blood collection timepoints.
    1.Evaluar la respuesta anamnésica a la presentación del antígeno de Ad26.COV2.S en el nivel de dosis de 1,25x1010 pv, administrado 4 meses después de la vacunación 2 (pauta de 2 dosis) o 6 meses después de la vacunación 1 (pauta de dosis única), 7 días después de la presentación del antígeno.
    2.Evaluar la seguridad y la reactogenicidad de la presentación del antígeno de Ad26.COV2.S en el nivel de dosis de 1,25x1010 pv, administrado 4 meses después de la vacunación 2 (pauta de 2 dosis) o 6 meses después de la vacunación 1 (pauta de dosis única).
    3.Evaluar la respuesta inmunitaria humoral a Ad26.COV2.S en todos los grupos, en todos los momentos de extracción de muestras de sangre.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Participant is 18 to 55 years of age, inclusive, or 65 years of age or older on the day of signing the ICF
    2. Participant must have a body mass index (BMI) <30.0 kg/m2.
    3. Participant 18 to 55 years of age, inclusive: Participant must be healthy, in the investigator’s clinical judgment, as confirmed by medical history, physical examination, and vital signs performed at screening, and must not have comorbidities related to an increased risk of severe COVID-19, except for smoking, which is allowed.
    Participant 65 years of age and older: in the investigator’s clinical judgment, participant must be either in good or stable health. Participant may have underlying illnesses, as long as the symptoms and signs are medically controlled and not considered to be comorbidities related to an increased risk of severe COVID-19, except for smoking, which is allowed. If on medication for a condition, the medication dose must have been stable for at least 12 weeks preceding vaccination and expected to remain stable for the duration of the study. Participant will be included on the basis of physical examination, medical history, and vital signs.
    4. All participants of childbearing potential must:
    a. Have a negative highly sensitive urine pregnancy test at screening.
    b. Have a negative highly sensitive urine pregnancy test immediately prior to each study vaccine administration.
    5. Participant agrees to not donate bone marrow, blood, and blood products from the first study vaccine administration until 3 months after receiving the last dose of study vaccine.
    1.Tener entre 18 y 55 años de edad, o 65 años en adelante inclusive, el día de la firma del formulario de consentimiento informado.
    2.Tener un índice de masa corporal (IMC) <30,0 kg/m2.
    3.Participantes de 18 a 55 años, incluídos: Estar sanos, según el criterio clínico del investigador, confirmado por los antecedentes médicos, la exploración física y las constantes vitales medidas en la selección, y no tener comorbilidades relacionadas con un mayor riesgo de padecer COVID-19 grave excepto por tabaquismo, lo cual está permitido.
    Participantes de 65 años en adelante:según el criterio del investigador, los participantes deben estar sanos o con salud estable. Los participantes pueden tener enfermedades subyacentes, siempre y cuando los síntomas y signos estén bajo control médico y no se consideren comorbilidades relacionadas con un mayor riesgo de padecer COVID-19 grave, excepto por tabaquismo, lo cual está permitido. Si está tomando medicamentos para una enfermedad, la dosis debe haber sido estable durante al menos 12 semanas antes de la vacunación, esperándose que permanezca estable durante la duración del estudio. Serán incluidos en base a un examen físico, historial médico y signos vitales.
    4.Las mujeres con capacidad de quedarse embarazadas:
    a.Tener una prueba de embarazo en orina de alta sensibilidad negativa en la selección.
    b.Tener una prueba de embarazo en orina de alta sensibilidad negativa inmediatamente antes de la administración de cada vacuna del estudio.
    5.Aceptar no donar médula ósea, sangre ni hemoderivados desde la primera administración de la vacuna del estudio hasta 3 meses después de recibir la última dosis de la vacuna del estudio.
    E.4Principal exclusion criteria
    1. Participant has a clinically significant acute illness (this does not include minor illnesses such as diarrhea or mild upper respiratory tract infection) or temperature ≥38.0ºC (100.4°F) within 24 hours prior to the planned first dose of study vaccine; randomization at a later date is permitted at the discretion of the investigator and after consultation with the sponsor.
    2. Participant has a history of malignancy within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy, which is considered cured with minimal risk of recurrence).
    3. Participant has a known or suspected allergy or history of anaphylaxis or other serious adverse reactions to vaccines or their excipients (including specifically the excipients of the study vaccine).
    4. Participant has abnormal function of the immune system.
    5. Participant has a history of any neurological disorders or seizures including Guillain-Barré syndrome, with the exception of febrile seizures during childhood.
    6. Participant has a history of chronic urticaria (recurrent hives), eczema or adult atopic dermatitis.
    7. Participant received treatment with immunoglobulins in the 3 months or blood products in the 4 months before the planned administration of the first dose of study vaccine or has any plans to receive such treatment during the study.
    8. Participant is a woman who is pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 3 months after the last dose of study vaccine.
    9. Participant has chronic active hepatitis B or hepatitis C infection per medical history.
    10. Participant previously received a coronavirus vaccine.
    11. Participant has a positive diagnostic test result for past (serological testing) or current (PCR based viral RNA detection) SARS-CoV-2 infection at screening.
    12. Participants with comorbidities that are or might be associated with an increased risk of progression to severe COVID-19, ie, participants with moderate-to severe asthma; chronic lung diseases such as chronic obstructive pulmonary disease (COPD) (including emphysema and chronic bronchitis), idiopathic pulmonary fibrosis and cystic fibrosis; diabetes (including type 1, type 2, or gestational); serious heart conditions, including heart failure, coronary artery disease, congenital heart disease, cardiomyopathies, and pulmonary hypertension or high blood pressure; obesity (BMI ≥ 30 kg/m2); chronic liver disease, including cirrhosis; sickle cell disease; thalassemia; cerebrovascular disease; neurologic conditions (dementia); and participants who live in nursing homes or long-term care facilities. This list is consistent with the list of conditions that increase the risk of progression to severe COVID-19 available at the CDC website at the time of writing of this protocol, except for smoking, which is allowed.
    13. Participant who is currently working in an occupation with a high risk of exposure to SARS-CoV-2 infection (eg, health care worker or emergency response personnel who work in close contact with SARS-CoV-2 infected patients) or considered at the investigator’s discretion to be at increased risk to acquire COVID-19 for any other reason.
    14. Participant who has had a known exposure to an individual with confirmed COVID-19 or SARS-CoV-2 infection within the past 2 weeks.
    15. History of confirmed SARS or MERS.
    1.Tener enfermedad aguda clínicamente significativa (esto no incluye enfermedades leves como diarrea o infección leve del tracto respiratorio superior) o temperatura ≥38,0ºC (100,4 F) en las 24 horas previas a la primera dosis programada de la vacuna del estudio; se permite la aleatorización en una fecha posterior según el criterio del investigador y previa consulta con el promotor.
    2.Tener antecedentes de tumor maligno en los 5 años anteriores a la selección (con la excepción del carcinoma escamoso y carcinoma basocelular cutáneo y el carcinoma in situ de cuello uterino, o tumores malignos que se consideren curados y con un riesgo de recurrencia mínimo).
    3.Tener una alergia conocida o antecedentes de anafilaxia u otras reacciones adversas graves a las vacunas o sus excipientes (incluidos específicamente los excipientes de la vacuna del estudio).
    4.Tener un funcionamiento anómalo del sistema inmunitario.
    5.Tener antecedentes de polineuropatía aguda incluyendo síndrome de Guillain-Barré, con la excepción de convulsiones febriles durante la infancia.
    6.Tener antecedentes de urticaria crónica (urticaria recurrente), eccema o dermatitis atópica del adulto.
    7.Haber recibido tratamiento con inmunoglobulinas en los 3 meses o hemoderivados en los 4 meses anteriores a la administración programada de la primera dosis de la vacuna del estudio o tener previsto recibir dicho tratamiento durante el estudio.
    8.Mujer embarazada, en periodo de lactancia o que tenga intención de quedarse embarazada durante el transcurso de este estudio o en los 3 meses siguientes a la última dosis de la vacuna del estudio.
    9.Tener infección crónica activa por hepatitis B o hepatitis C documentada en los antecedentes médicos.
    10.Participantes que previamente hayan recibido otra vacuna para coronavirus.
    11.Tener un resultado positivo de la prueba de diagnóstico para la infección por SARS-CoV-2 pasada (prueba serológica) o actual (detección de ARN vírico) en la selección.
    12.Participantes con comorbilidades que están o podrían estar asociadas con un mayor riesgo de progresión a COVID-19 grave, es decir, participantes con asma de moderada a grave; enfermedades pulmonares crónicas como la enfermedad pulmonar obstructiva crónica (EPOC) (incluyendo enfisema y bronquitis crónica), fibrosis pulmonar idiopática y fibrosis quística; diabetes (incluyendo tipo 1, tipo 2 o gestacional); afecciones cardíacas graves, incluida la insuficiencia cardíaca, la enfermedad coronaria, la enfermedad cardíaca congénita, las cardiomiopatías y la hipertensión pulmonar o la presión arterial alta; la obesidad (IMC ≥ 30 kg/m2); las enfermedades hepáticas crónicas, incluida la cirrosis; la anemia drepanocítica; la talasemia; las enfermedades cerebrovasculares; las afecciones neurológicas (demencia); y los participantes que viven en residencias de ancianos o centros de atención a largo plazo. Esta lista es consistente con la lista de condiciones que aumentan el riesgo de progresión a COVID-19 grave disponible en el sitio web de los CDC en el momento de la redacción de este protocolo, excepto el fumar, que está permitido.
    13.Trabajar actualmente en un puesto con alto riesgo de exposición a la infección por SARS-CoV-2 (p. ej., trabajador sanitario o personal de urgencias que trabajan en estrecho contacto con pacientes infectados por SARS-CoV-2). o que a criterio del investigador pudieran incrementar su riesgo de adquirir COVID-19 por alguna razón.
    14. Participante que ha tenido una exposición conocida a un individuo con infección confirmada de COVID-19 o SARS-CoV-2 en las últimas 2 semanas.
    15. Historia de SARS o MERS confirmada.
    E.5 End points
    E.5.1Primary end point(s)
    1a. Serological response to vaccination as measured by virus neutralization assay (VNA) titers and enzyme-linked immunosorbent assay (S-ELISA, ELISA Units/mL [EU/mL]), 28 days after Vaccination 2.
    1b. Antibody geometric mean titers (GMTs) (VNA) and geometric mean concentrations (GMCs) (S-ELISA), 28 days after Vaccination 2.
    2a. Serological response to vaccination as measured by VNA titers and ELISA (S-ELISA, EU/mL), 28 days after Vaccination 1.
    2b. Antibody GMTs (VNA) and GMCs (S-ELISA), 28 days after Vaccination 1.
    3a. Serological response to vaccination as measured by VNA titers and ELISA (S-ELISA, EU/mL), 28 days after Vaccination 2.
    3b. Antibody GMTs (VNA) and GMCs (S-ELISA), 28 days after Vaccination 2.
    4a. Solicited local and systemic adverse events (AEs) for 7 days after each vaccination.
    4b. Unsolicited AEs for 28 days after each vaccination.
    4c. Serious adverse events (SAEs) throughout the study (from first vaccination until end of the study).
    1a.Respuesta serológica a la vacunación medida mediante los valores de la prueba de neutralización del virus (VNA) y el ensayo de inmunoabsorción ligado a enzima (S-ELISA, ELISA Unidades/ml [EU/ml]), 28 días después de la vacunación 2.
    1b.Valores medios geométricos de anticuerpos (GMT) (VNA) y concentraciones medias geométricas (GMC) (S-ELISA), 28 días después de la vacunación
    2a.Respuesta serológica a la vacunación medida mediante los valores de VNA y ELISA (S-ELISA EU/ml, 28 días después de la vacunación 1.
    2b.GMT de anticuerpos (VNA) y GMC (S ELISA), 28 días después de la vacunación 1.
    3a.Respuesta serológica a la vacunación medida mediante los valores de VNA y ELISA (S-ELISA, EU/ml), 28 días después de la vacunación 2.
    3b.GMT de anticuerpos (VNA) y GMC (S ELISA), 28 días después de la vacunación 2.
    4a.Acontecimientos adversos (AA) locales y sistémicos solicitados durante 7 días después de cada vacunación.
    4b.AA no solicitados durante 28 días después de cada vacunación.
    4c.Acontecimientos adversos graves (AAG) durante todo el estudio (desde la primera vacunación hasta el final del estudio.
    E.5.1.1Timepoint(s) of evaluation of this end point
    7 or 28 days after each vaccination
    Safety endpoints - continuous throughout the study
    7 o 28 días después de cada vacunación
    Seguridad- A lo largo de todo el estudio
    E.5.2Secondary end point(s)
    1a. Serological response to vaccination as measured by VNA titers and ELISA (S-ELISA, EU/mL), 7 days after antigen presentation.
    1b. Antibody GMTs (VNA) and GMCs (S-ELISA), 7 days after antigen presentation.
    2a. Solicited local and systemic AEs for 7 days after antigen presentation.
    2b. Unsolicited AEs for 28 days after antigen presentation.
    2c. SAEs throughout the study (from antigen presentation until end of the study).
    3a. Neutralizing antibody titers to the wild-type SARS-CoV-2 virus and/or pseudovirion expressing S protein as measured by VNA, at all blood collection timepoints.
    3b. Binding antibody titers to SARS-CoV-2 or individual SARS-CoV-2 proteins (eg, S protein) as measured by ELISA, at all blood collection timepoints.
    1a.Respuesta serológica a la vacunación medida mediante los valores de VNA y ELISA (S-ELISA, EU/ml), 7 días después de la presentación del antígeno.
    1b.GMT de anticuerpos (VNA) y GMC (S ELISA), 7 días después de la presentación del antígeno.
    2a.AA locales y sistémicos solicitados durante 7 días después de la presentación del antígeno.
    2b.AA no solicitados durante 28 días después de la presentación del antígeno.
    2c.AAG durante todo el estudio (desde la presentación del antígeno hasta el final del estudio).
    3a.Valores de anticuerpos neutralizantes para el virus SARS-CoV-2 de tipo salvaje y/o pseudovirión que expresan la proteína S medidos mediante VNA, en todos los momentos de extracción de muestras de sangre.
    E.5.2.1Timepoint(s) of evaluation of this end point
    - 7 or 28 days after antigen presentation
    - at all blood collection timepoints
    - 7 o 28 días después de la presentación del antígeno
    - en todos los puntos de recolección de sangre
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis Yes
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy No
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Reactogenicity and Immunogenicity
    Reactogeneicidad e inmunidad
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial10
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned3
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA9
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    Última visita del último paciente
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months4
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months4
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 367
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 183
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers Yes
    F.3.2Patients No
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state190
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 550
    F.4.2.2In the whole clinical trial 550
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    Ninguno
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2020-08-28
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2020-08-25
    P. End of Trial
    P.End of Trial StatusTemporarily Halted
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2021 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA